JPH11500110A - Tnf−抑制用製剤 - Google Patents
Tnf−抑制用製剤Info
- Publication number
- JPH11500110A JPH11500110A JP8523903A JP52390396A JPH11500110A JP H11500110 A JPH11500110 A JP H11500110A JP 8523903 A JP8523903 A JP 8523903A JP 52390396 A JP52390396 A JP 52390396A JP H11500110 A JPH11500110 A JP H11500110A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- manufacture
- medicament
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式I: [式中、 R1は、C1〜C4−アルキルを表し、 R2は、C1〜C6−アルキル、C3〜C7−シクロアルキル、C3〜C7−シク ロアルキル−C1〜C2−アルキル、C2〜C6−アルケニル、C3〜C7−アルキニ ル、複素環又は1個以上のハロゲン、ヒドロキシ、カルボキシ、C1〜C4−アル コキシ、C1〜C4−アルコキシカルボニル又は場合によりC1〜C4−アルキルで 置換されたアミノ基で置換されているC1〜C6−アルキルを表し、 R3は、水素、C1〜C6−アルキル、アシル、アリール、アラルキル、1又 は2個のメチル基で置換されたアリールを表し、かつ R4は、水素又はC1〜C6−アルキルを表す]の光学活性な化合物又はラセミ 化合物を、腫瘍壊死因子の活性化に起因する疾患の治療のための薬剤を製造する ために使用すること。 2. 請求項1に記載の5−(3−シクロペンチルオキシ−4−メトキシフェニ ル)−5−メチル−2−オキサゾリジノンの使用。 3. 請求項1に記載の5−(3−プロポキシ−4−メトキシフェニル)−5−メ チル−2−オキサゾリジノンの使用。 4. 請求項1に記載の式Iの化合物を、中枢神経系の炎症性疾患を治療するた めの薬剤を製造するために使用すること。 5. 請求項1に記載の式Iの化合物を、多発性硬化症を治療するための薬剤を 製造するために使用すること。 6. 請求項1に記載の式Iの化合物を、感染症を治療するための薬剤を製造す るために使用すること。 7. 請求項1に記載の式Iの化合物を、骨吸収疾患を治療するための薬剤を製 造するために使用すること。 8. 請求項1に記載の式Iの化合物を、肺疾患を治療するための薬剤を製造す るために使用すること。 9. 請求項1に記載の式Iの化合物を、皮膚の炎症性疾患を治療するための薬 剤を製造するために使用すること。 10. 請求項1に記載の式Iの化合物を、自己免疫疾患を治療するための薬剤 を製造するために使用すること。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19505516.0 | 1995-02-10 | ||
DE19505516 | 1995-02-10 | ||
PCT/DE1996/000257 WO1996024350A1 (de) | 1995-02-10 | 1996-02-09 | Pharmazeutische präparate zur tnf-inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11500110A true JPH11500110A (ja) | 1999-01-06 |
Family
ID=7754327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8523903A Ceased JPH11500110A (ja) | 1995-02-10 | 1996-02-09 | Tnf−抑制用製剤 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6117895A (ja) |
EP (1) | EP0804192A1 (ja) |
JP (1) | JPH11500110A (ja) |
KR (1) | KR19980702116A (ja) |
CN (1) | CN1173818A (ja) |
AU (1) | AU706159B2 (ja) |
CZ (1) | CZ290671B6 (ja) |
FI (1) | FI973277A (ja) |
HU (1) | HUP9702408A3 (ja) |
IL (1) | IL117090A (ja) |
MX (1) | MX9706086A (ja) |
SK (1) | SK283821B6 (ja) |
WO (1) | WO1996024350A1 (ja) |
ZA (1) | ZA961081B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8747998A (en) * | 1997-08-21 | 1999-03-16 | Takeda Chemical Industries Ltd. | Anti-inflammatory agent |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
TW200732313A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
DE2541855A1 (de) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
FR2358155A1 (fr) * | 1976-07-15 | 1978-02-10 | Lapinet Eugene | Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses |
DE2655369A1 (de) * | 1976-12-03 | 1978-06-08 | Schering Ag | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
US5783591A (en) * | 1984-10-19 | 1998-07-21 | Schering Aktiengesellschaft | Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation |
DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
DE3639225A1 (de) * | 1986-11-14 | 1988-05-19 | Schering Ag | Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka |
KR920702621A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
DE69128627T2 (de) * | 1990-08-03 | 1998-07-02 | Smithkline Beecham Corp | Tnf-inhibitoren |
PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
US5227369A (en) * | 1991-07-11 | 1993-07-13 | The Regents Of The University Of California | Compositions and methods for inhibiting leukocyte adhesion to cns myelin |
GB9204808D0 (en) * | 1992-03-04 | 1992-04-15 | Rhone Poulenc Rorer Ltd | Novel compositions of matter |
US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
-
1996
- 1996-02-09 JP JP8523903A patent/JPH11500110A/ja not_active Ceased
- 1996-02-09 HU HU9702408A patent/HUP9702408A3/hu unknown
- 1996-02-09 AU AU47122/96A patent/AU706159B2/en not_active Ceased
- 1996-02-09 MX MX9706086A patent/MX9706086A/es not_active IP Right Cessation
- 1996-02-09 IL IL11709096A patent/IL117090A/xx not_active IP Right Cessation
- 1996-02-09 SK SK1073-97A patent/SK283821B6/sk unknown
- 1996-02-09 WO PCT/DE1996/000257 patent/WO1996024350A1/de not_active Application Discontinuation
- 1996-02-09 ZA ZA961081A patent/ZA961081B/xx unknown
- 1996-02-09 CN CN96191868A patent/CN1173818A/zh active Pending
- 1996-02-09 EP EP96902870A patent/EP0804192A1/de not_active Withdrawn
- 1996-02-09 CZ CZ19972513A patent/CZ290671B6/cs not_active IP Right Cessation
- 1996-02-10 KR KR1019970705511A patent/KR19980702116A/ko not_active Application Discontinuation
- 1996-07-18 US US08/683,467 patent/US6117895A/en not_active Expired - Fee Related
-
1997
- 1997-08-08 FI FI973277A patent/FI973277A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU4712296A (en) | 1996-08-27 |
HUP9702408A2 (hu) | 1998-05-28 |
FI973277A0 (fi) | 1997-08-08 |
CZ290671B6 (cs) | 2002-09-11 |
EP0804192A1 (de) | 1997-11-05 |
IL117090A (en) | 2000-07-26 |
CZ251397A3 (en) | 1997-12-17 |
HUP9702408A3 (en) | 2000-08-28 |
WO1996024350A1 (de) | 1996-08-15 |
SK107397A3 (en) | 1997-12-10 |
SK283821B6 (sk) | 2004-02-03 |
MX9706086A (es) | 1997-10-31 |
AU706159B2 (en) | 1999-06-10 |
FI973277A (fi) | 1997-08-08 |
ZA961081B (en) | 1996-10-15 |
US6117895A (en) | 2000-09-12 |
KR19980702116A (ko) | 1998-07-15 |
CN1173818A (zh) | 1998-02-18 |
IL117090A0 (en) | 1996-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Taylor et al. | Bran tablets and diverticular disease. | |
US6025376A (en) | Chiral methylphenyloxazolidinones | |
KR20070065888A (ko) | 염증성 장질환을 치료하기 위한(z)-2-시아노-3-하이드록시-부트-2-엔산-(4'-트리플루오로메틸페닐)-아미드의 용도 | |
US4330558A (en) | Pharmaceutical composition and method for treating peripheral orthostatic hypotension | |
AU752192B2 (en) | The use of valproic acid analog for the treatment and prevention of migraine and affective illness | |
JPH11500110A (ja) | Tnf−抑制用製剤 | |
JP2002506449A (ja) | 炎症性疾患の処置用医薬の製造におけるガバ類縁体、たとえばガバペンチンの使用 | |
FR2600891A1 (fr) | Produit pharmaceutique pour la stimulation de l'apprentissage et l'amelioration de la memoire contenant comme principe actif, le chlorhydrate de 9-amino-2,3, 5,6,7,8,-hexahydro-14-cyclopenta(b)quinoline monohydrate | |
JP6522845B1 (ja) | 非閉塞性肥大型心筋症治療薬 | |
FR2635461A1 (fr) | Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress | |
US20050288371A1 (en) | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis | |
US4906649A (en) | Use of a compound for the treatment of sleep disorders and depression | |
JPH0196132A (ja) | 精神分裂症を治療するためのある種の化合物の使用 | |
Farmer et al. | Comparative beta-adrenoceptive stimulant properties of salbutamol (AH 3365), orciprenaline and soterenol (MJ 1992). | |
CA2212440C (en) | Pharmaceutical preparations for tnf inhibition | |
JP6447496B2 (ja) | 多発性硬化症の治療剤又は予防剤 | |
US3885045A (en) | Therapeutic composition containing 1-(2-hydroxy-2-indanyl)-propylamine | |
US7763625B2 (en) | Agents for treating migraine | |
JPH05503510A (ja) | 光学的に純粋な(s)―アテノロールを含む組成物と方法 | |
US5441962A (en) | Method for treating hyperlipemia | |
JP4120713B2 (ja) | 多発性硬化症治療剤 | |
US3784703A (en) | Method of treating hypertension | |
NL8203226A (nl) | (-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido-4,3-bindool, werkwijze ter bereiding ervan, alsmede farmaceutische preparaten die deze verbinding bevatten. | |
DE2026402C3 (de) | Derivate der 5- (2- [(l-Methyl-3- phenylpropyl)amino] -äthyl} -salicylsäure, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate | |
JPWO2003006024A1 (ja) | ピリミジン誘導体を含有する医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20061016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070613 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070731 |